Therapy of refractory nontuberculous mycobacterial lung disease
The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tu...
Uložené v:
| Vydané v: | Current opinion in infectious diseases Ročník 25; číslo 2; s. 218 |
|---|---|
| Hlavní autori: | , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.04.2012
|
| Predmet: | |
| ISSN: | 1473-6527, 1473-6527 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tuberculosis) treatment failure.
Critical elements for the successful treatment of Mycobacterium avium complex (MAC) lung disease include aggressive first therapeutic attempts and avoidance of the emergence of macrolide-resistant MAC strains, which are associated with worse treatment response and increased mortality. Reliably effective therapy for M. abscessus lung disease remains elusive but still usually requires parenteral agents. Lung resection surgery for selected patients is an important adjunct for both MAC and M. abscessus lung disease. Aside from surgery and parenteral antibiotics, there are very few data to support the efficacy of other drugs or interventions for patients who have failed the first-line therapy.
Clinicians who manage NTM lung disease will inevitably encounter patients who fail the first-line therapy. The choices for effective treatment of these patients are depressingly sparse. It is critically important to avoid creation of macrolide-resistant MAC strains and to carefully choose those NTM lung disease patients who will benefit from surgery. |
|---|---|
| AbstractList | The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tuberculosis) treatment failure.
Critical elements for the successful treatment of Mycobacterium avium complex (MAC) lung disease include aggressive first therapeutic attempts and avoidance of the emergence of macrolide-resistant MAC strains, which are associated with worse treatment response and increased mortality. Reliably effective therapy for M. abscessus lung disease remains elusive but still usually requires parenteral agents. Lung resection surgery for selected patients is an important adjunct for both MAC and M. abscessus lung disease. Aside from surgery and parenteral antibiotics, there are very few data to support the efficacy of other drugs or interventions for patients who have failed the first-line therapy.
Clinicians who manage NTM lung disease will inevitably encounter patients who fail the first-line therapy. The choices for effective treatment of these patients are depressingly sparse. It is critically important to avoid creation of macrolide-resistant MAC strains and to carefully choose those NTM lung disease patients who will benefit from surgery. The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tuberculosis) treatment failure.PURPOSE OF REVIEWThe prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tuberculosis) treatment failure.Critical elements for the successful treatment of Mycobacterium avium complex (MAC) lung disease include aggressive first therapeutic attempts and avoidance of the emergence of macrolide-resistant MAC strains, which are associated with worse treatment response and increased mortality. Reliably effective therapy for M. abscessus lung disease remains elusive but still usually requires parenteral agents. Lung resection surgery for selected patients is an important adjunct for both MAC and M. abscessus lung disease. Aside from surgery and parenteral antibiotics, there are very few data to support the efficacy of other drugs or interventions for patients who have failed the first-line therapy.RECENT FINDINGSCritical elements for the successful treatment of Mycobacterium avium complex (MAC) lung disease include aggressive first therapeutic attempts and avoidance of the emergence of macrolide-resistant MAC strains, which are associated with worse treatment response and increased mortality. Reliably effective therapy for M. abscessus lung disease remains elusive but still usually requires parenteral agents. Lung resection surgery for selected patients is an important adjunct for both MAC and M. abscessus lung disease. Aside from surgery and parenteral antibiotics, there are very few data to support the efficacy of other drugs or interventions for patients who have failed the first-line therapy.Clinicians who manage NTM lung disease will inevitably encounter patients who fail the first-line therapy. The choices for effective treatment of these patients are depressingly sparse. It is critically important to avoid creation of macrolide-resistant MAC strains and to carefully choose those NTM lung disease patients who will benefit from surgery.SUMMARYClinicians who manage NTM lung disease will inevitably encounter patients who fail the first-line therapy. The choices for effective treatment of these patients are depressingly sparse. It is critically important to avoid creation of macrolide-resistant MAC strains and to carefully choose those NTM lung disease patients who will benefit from surgery. |
| Author | Aksamit, Timothy R Griffith, David E |
| Author_xml | – sequence: 1 givenname: David E surname: Griffith fullname: Griffith, David E email: david.griffith@uthct.edu organization: University of Texas Health Science Center, Tyler, Tyler, Texas 75708, USA. david.griffith@uthct.edu – sequence: 2 givenname: Timothy R surname: Aksamit fullname: Aksamit, Timothy R |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22327466$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNT8lKxEAUbGTEWfQPRHLzlLH3Tp9EBjcYGITxHHp5rZFsdieH_L0BR_BUBVXUskaLtmsBoWuCtwRrdfe2O2yxxYQBowUThBjJz9CKcMVyKaha_ONLtE7pC2NCNZYXaEkpo4pLuUL3x0-Ipp-yLmQRQjRu6OKUzV3DaCG6se7GlDWT6-wsQaxMndVj-5H5KoFJcInOg6kTXJ1wg96fHo-7l3x_eH7dPexzxynhefCKh8ILh4PUnjtDiGW4CIVijNmgA7aguPNCU8ms0IIZS4U1wXsDWhZ0g25_c_vYfY-QhrKpkoO6Ni3MC0tNhSJKCzE7b07O0Tbgyz5WjYlT-feZ_gCRh1z3 |
| CitedBy_id | crossref_primary_10_1128_AAC_02016_12 crossref_primary_10_1007_s40506_015_0061_5 crossref_primary_10_1016_j_rmed_2025_108220 crossref_primary_10_1080_14787210_2020_1720650 crossref_primary_10_1164_rccm_201111_2005OC crossref_primary_10_1128_AAC_00700_16 crossref_primary_10_1186_s12879_018_3113_x crossref_primary_10_1186_s12931_020_01420_1 crossref_primary_10_1186_s12879_015_0823_1 crossref_primary_10_1080_17476348_2017_1386563 crossref_primary_10_1007_s00108_015_0014_6 crossref_primary_10_1016_j_chest_2021_03_070 crossref_primary_10_2147_PROM_S272075 crossref_primary_10_1164_rccm_201408_1545OC crossref_primary_10_1513_AnnalsATS_201304_085OC crossref_primary_10_1016_j_rmed_2018_07_003 crossref_primary_10_1183_23120541_00109_2018 crossref_primary_10_1186_s12879_016_1384_7 crossref_primary_10_3389_fimmu_2021_728742 crossref_primary_10_1080_17476348_2021_1987891 crossref_primary_10_1186_s12931_022_02299_w crossref_primary_10_1016_j_lfs_2020_117541 crossref_primary_10_1128_AAC_00648_15 crossref_primary_10_1128_AAC_02281_12 crossref_primary_10_1016_j_ijid_2014_02_014 crossref_primary_10_1590_0037_8682_0097_2013 crossref_primary_10_3389_fmicb_2022_821820 crossref_primary_10_1093_femspd_ftx107 crossref_primary_10_1128_AAC_04577_14 crossref_primary_10_1186_s12913_018_3489_8 crossref_primary_10_1128_aac_02212_21 crossref_primary_10_1016_j_jiac_2014_05_010 crossref_primary_10_1038_s41429_019_0245_1 crossref_primary_10_1016_j_jcf_2014_07_004 crossref_primary_10_1016_j_mayocp_2019_10_024 crossref_primary_10_1007_s10156_012_0518_0 crossref_primary_10_1093_cid_ciaa252 crossref_primary_10_1080_17460441_2019_1629414 crossref_primary_10_1586_17476348_2016_1165611 crossref_primary_10_1002_ccr3_898 crossref_primary_10_3390_ijms21124191 crossref_primary_10_1128_microbiolspec_MGM2_0034_2013 crossref_primary_10_1093_cid_cix274 crossref_primary_10_1016_j_jfma_2020_04_029 crossref_primary_10_1513_AnnalsATS_202008_925OC crossref_primary_10_1111_1440_1681_13651 crossref_primary_10_1164_rccm_201807_1318OC crossref_primary_10_1371_journal_pone_0087909 crossref_primary_10_1016_j_jiac_2019_10_009 crossref_primary_10_1371_journal_pone_0279714 crossref_primary_10_1136_bcr_2023_255845 crossref_primary_10_1016_j_resinv_2022_05_006 crossref_primary_10_1128_AAC_00978_21 crossref_primary_10_1164_rccm_201405_0884OC crossref_primary_10_1164_rccm_201604_0700OC crossref_primary_10_1016_j_rmcr_2021_101506 crossref_primary_10_1111_imm_12131 crossref_primary_10_1016_j_medcle_2017_12_031 crossref_primary_10_1155_2014_919474 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/QCO.0b013e3283511a64 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1473-6527 |
| ExternalDocumentID | 22327466 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- .-D .GJ .XZ .Z2 01Q 0R~ 4Q1 4Q2 4Q3 53G 5GY 5VS 6PF 71W 8L- AAAAV AAHPQ AAIQE AAJCS AAMTA AARTV AASCR AAUEB AAWTL AAYEP ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABXYN ABZAD ABZZY ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFMBP AFMFG AFNMH AFSOK AGINI AHQNM AHQVU AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK BS7 C45 CAG CGR COF CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 L-C L7B LEELO N9A NPM N~M O9- OAG OAH OCUKA ODA ODMTH OHYEH OLC OLG OPUJH ORVUJ OUVQU OVD OVDKG OVDNE OVKID OVOZU OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW UAP V2I VVN W3M WOQ WOW X3V X3W XO3 XXN XYM YFH YOC ZFV ZZMQN 7X8 ABPXF ADKSD |
| ID | FETCH-LOGICAL-c4214-fd74f8d5c0f69d4ca11b308f87333bf9f0be74cd59263b5953ab25bafddae9682 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 75 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000300896700015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1473-6527 |
| IngestDate | Mon Sep 08 13:24:46 EDT 2025 Thu Apr 03 07:01:08 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4214-fd74f8d5c0f69d4ca11b308f87333bf9f0be74cd59263b5953ab25bafddae9682 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 22327466 |
| PQID | 925717955 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_925717955 pubmed_primary_22327466 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-Apr 20120401 |
| PublicationDateYYYYMMDD | 2012-04-01 |
| PublicationDate_xml | – month: 04 year: 2012 text: 2012-Apr |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Current opinion in infectious diseases |
| PublicationTitleAlternate | Curr Opin Infect Dis |
| PublicationYear | 2012 |
| SSID | ssj0012906 |
| Score | 2.2987392 |
| SecondaryResourceType | review_article |
| Snippet | The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 218 |
| SubjectTerms | Anti-Bacterial Agents - therapeutic use Communicable Diseases, Emerging - therapy Drug Resistance, Bacterial Humans Lung Diseases - microbiology Lung Diseases - therapy Mycobacterium avium-intracellulare Infection - therapy Mycobacterium Infections - therapy Risk Factors Treatment Failure |
| Title | Therapy of refractory nontuberculous mycobacterial lung disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22327466 https://www.proquest.com/docview/925717955 |
| Volume | 25 |
| WOSCitedRecordID | wos000300896700015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS0MxEA5qRby4L3XjHbyGvpflJTkVEYuX1goVeitZQah9tbVC_72Tt-hJPHjJLWEYvlmSmXyD0G0qhdQ2VxiiE8HMGbA5qygOEJqC1S71QZfDJsRgIMdjNax7c5Z1W2XjE0tH7Qob38g7CrAF4OG8O3_HcWhULK7WEzQ2UYtCJhNBLcY_RYTIZF5-LhIU55yI5uecEp3n-6fmCTASjmWZjpQDv-WYZazp7f9TygO0VyeZyV2FikO04WdHaKdfl9GPUXdUcQkkRUggQi7KmTvrZFZAADJ-YVfTYrVM3tYWjL0kc4bDpuAVkrqcc4Jeeg-j-0dcT1LAlpGM4eAEC9Jxm4ZcOWZ1lhmayiAFpdQEFVLjBbOOK5JTwxWn2hBudHBOe5VLcoq2QAZ_jhJnPCfecmGpZFnmFaU6lRoOUcxnIrRR0mhmAkiN5Qc98yD15Fs3bXRWaXcyrxg1JpCjwO04zy_-3nyJdiFnIVXzzBVqBbBSf4227efH63JxUyIA1sGw_wV2Z7v- |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapy+of+refractory+nontuberculous+mycobacterial+lung+disease&rft.jtitle=Current+opinion+in+infectious+diseases&rft.au=Griffith%2C+David+E&rft.au=Aksamit%2C+Timothy+R&rft.date=2012-04-01&rft.eissn=1473-6527&rft.volume=25&rft.issue=2&rft.spage=218&rft_id=info:doi/10.1097%2FQCO.0b013e3283511a64&rft_id=info%3Apmid%2F22327466&rft_id=info%3Apmid%2F22327466&rft.externalDocID=22327466 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-6527&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-6527&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-6527&client=summon |